Bryant J, Picot J, Baxter L, Levitt G, Sullivan I, Clegg A
Southampton Health Technology Assessments Centre, Wessex Institute for Health Research and Development, Mailpoint 728, Boldrewood, University of Southampton, Southampton SO16 7PX, United Kingdom.
Eur J Cancer. 2007 Sep;43(13):1959-66. doi: 10.1016/j.ejca.2007.06.012. Epub 2007 Aug 3.
To evaluate the effectiveness of cardiac markers to quantify anthracycline-induced cardiotoxicity in children with cancer.
Systematic review using a priori methods.
Seven studies, all with methodological limitations, were identified. One RCT suggests that cardiac troponin can be used to assess the effectiveness of the cardio-protective agent dexrazoxane. Cohort studies suggest that atrial natriuretic peptide and brain (B-type) natriuretic peptide are elevated in some subgroups of patients compared with healthy children; NT-pro-BNP levels are significantly elevated in children with cardiac dysfunction compared with those without; serum lipid peroxide is higher in children who have received doxorubicin compared with children not receiving doxorubicin; there are no differences in carnitine levels between children treated with doxorubicin and a healthy control group.
The limited evidence makes conclusions difficult. Research is needed to fill this important evidence gap and link short-term changes in cardiac markers to longer-term cardiac damage.
评估心脏标志物对量化癌症患儿蒽环类药物所致心脏毒性的有效性。
采用先验方法进行系统评价。
共纳入7项研究,均存在方法学局限性。一项随机对照试验表明,心肌肌钙蛋白可用于评估心脏保护剂右丙亚胺的有效性。队列研究表明,与健康儿童相比,某些患者亚组的心房利钠肽和脑(B型)利钠肽水平升高;与无心脏功能障碍的儿童相比,心脏功能障碍儿童的N末端B型利钠肽原(NT-pro-BNP)水平显著升高;与未接受多柔比星治疗的儿童相比,接受多柔比星治疗的儿童血清脂质过氧化物水平更高;接受多柔比星治疗的儿童与健康对照组之间的肉碱水平无差异。
证据有限,难以得出结论。需要开展研究以填补这一重要的证据空白,并将心脏标志物的短期变化与长期心脏损害联系起来。